Expect to See Tirzepatide on Home Med Lists
July 2022
You’ll see patients coming in on the new injectable tirzepatide (Mounjaro)...the first “twincretin” for type 2 diabetes.
Think of it as similar to a glucagon-like peptide-1 (GLP-1) agonist...but it’s also a glucose-dependent insulinotropic polypeptide (GIP) agonist. More twincretins are in the works.
Both hormones are secreted in the gut in response to food...so the dual mechanism doesn’t seem to increase risk of hypoglycemia.Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote